Pilocytic astrocytoma (PA) is the most common pediatric brain tumor in children. PAs are a distinct histologic and biologic subset of glioma that have a slow growth rate and may even spontaneously regress. These tumors tend to arise in the cerebellum and chiasmatic/hypothalamic region, but can also occur in other regions of the central nervous system. Dissemination is uncommon, but may occur in newly diagnosed PAs. Alterations in the Ras/RAF/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway (Ras/ERK) have been discovered in a majority of PAs, with KIAA1549-BRAF fusions being the most commonly identified alteration. Children with neurofibromatosis 1 are predisposed to developing PAs, primarily within the optic pathway. When required, treatment consists of surgery, chemotherapy, and/or radiation, although new molecular agents targeting the Ras/ERK and related signaling pathways are promising new approaches. The 10-year survival rates are greater than 90% in pediatric patients; however, they are poorer in adults. Tumors that are amenable to complete resection (i.e., cerebellum and cortex) have the best overall survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/B978-0-12-802997-8.00020-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients.
Clin Chem
January 2025
Broad Institute of MIT and Harvard, Cambridge, MA, United States.
Background: Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from the body-thereby, allowing more cfDNA to be sampled-has been proposed to improve the performance of liquid biopsy diagnostics. However, there is a paucity of clinical data on the effect of higher cfDNA recovery.
View Article and Find Full Text PDFImply on diagnosis and early prognosis of preoperative [Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin.
Sci Rep
January 2025
Nuclear Medicine Department, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
PET/CT targeting prostate-specific membrane antigen (PSMA) is commonly used in patients with prostate cancer. PSMA has been found in other solid tumours, including primary brain tumours. The aim of this study was to evaluate the usefulness of [Ga]Ga-PSMA-11 PET/CT for preoperative diagnosis and 2-year prognosis.
View Article and Find Full Text PDFInvasion of glioma cells through confined space requires membrane tension regulation and mechano-electrical coupling via Plexin-B2.
Nat Commun
January 2025
Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Glioblastoma (GBM) is a malignant brain tumor with diffuse infiltration. Here, we demonstrate how GBM cells usurp guidance receptor Plexin-B2 for confined migration through restricted space. Using live-cell imaging to track GBM cells negotiating microchannels, we reveal endocytic vesicle accumulation at cell front and filamentous actin assembly at cell rear in a polarized manner.
View Article and Find Full Text PDFS100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture.
Theranostics
January 2025
Neurooncology Unit, Instituto de Investigación Biomédicas I+12, Hospital Universitario 12 de Octubre, Madrid 28041, Spain.
Article Synopsis
- GBM IDH wild type (GBM IDH wt) is linked to bad outcomes and intense inflammatory processes that help tumors grow and attract immune cells, making them more aggressive.
- Researchers utilized RNA-seq and bioinformatics tools to explore how inflammatory molecules, specifically S100A proteins, play a role in glioma, finding a notable increase in S100A expression in GBM IDH wt compared to IDH mutants.
- The study identified specific functions of S100A9, A11, and A13 in different regions of the glioma microenvironment, suggesting potential therapeutic strategies, such as using the RAGE inhibitor Azeliragon, currently in clinical trials, to counteract these inflammatory effects.
Elimination of High-grade Gliomas Through Induced Cytolysis, Elucidated by Two Patient Cases.
Anticancer Res
January 2025
Department of Medical Sciences, Clinical Chemistry, University of Uppsala, Uppsala, Sweden
Background/aim: Glioblastoma multiforme (GBM) is the most common and aggressive form of primary malignant tumors in the central nervous system of adults. In practice, all patients with GBM experience relapse, and treatment options become limited following first-line therapy. We previously reported a new, successful treatment approach for a GBM patient, implemented in direct conjunction with surgical intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!